Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck, GSK In Kidney Cancer Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Merck, GSK In Kidney Cancer Alliance

To evaluate combination regimen

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck has initiated a clinical trial to evaluate the combination of its investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline’s orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma. The Phase I/II trial will evaluate the safety and efficacy of MK-3475 and pazopanib in treatment naïve patients with advanced renal cell carcinoma.  
 
The companies have also entered a collaboration to study MK-3475 with pazopanib and other agents in GSK’s portfolio in the future. Additional terms were not disclosed.
 
“Collaborations like this are central to Merck’s strategy to evaluate the potential of MK-3475 for the treatment of cancer,” said Iain Dukes, senior vice president, Licensing and External Scientific Affairs, Merck Research Laboratories. “We look forward to initiating further collaborations to investigate MK-3475 in combination with other anti-cancer agents across a range of tumor types.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics